These findings indicate that Gala-SR is effective systemically, that may also of great promise for the therapy of systemic inflammatory diseases related to RORα abnormalities, such as primary Sjogren’s syndrome,49 diabetes,50 and systemic lupus erythematosus.51 This evidence concerns the gene RORA and Sjogren syndrome.